Abiomed Heart Pump Recall Lawsuit Claims

July 10, 2024 — The FDA has issued a Class I Recall, the highest warning on the Abiomed Heart Pump.

Over the past year, medical device giant Abiomed has found itself embroiled in a series of alarming product recalls and regulatory actions concerning its flagship Impella line of heart pumps. These temporary ventricular assist devices, designed to support cardiovascular function during high-risk procedures or acute heart failure, have been linked to a distressing number of serious injuries and deaths thus leading to lawsuits.

The Schmidt National Law Group is now helping victims who may have experienced any serious side effects from this recalled Abiomed heart device file claims, we expect large cash settlements from claims filed.

The latest development, a Class I recall initiated in December 2023, has thrust Abiomed into the harsh spotlight once again. This most severe category of recall was prompted by the risk of the Impella pump’s catheter perforating or rupturing the heart’s left ventricle wall during insertion or repositioning.

Use of the affected pumps could result in perforation or free wall rupture, hypertension, lack of blood flow and death as per the FDA recall notice.

According to the FDA’s notice, this potentially catastrophic complication has already resulted in 129 reports of severe injury, including 49 fatalities.

Which Abiomed Heart Pumps Were Recalled?

Encompassing over 92,000 devices distributed globally between October 2021 and October 2023, the recall impacts Abiomed’s entire Impella product line: the 2.5, CP, 5.0, 5.5, and LD models. In response, the company has updated its instructions for use, emphasizing the critical need for imaging guidance when advancing or manipulating the pump catheter. Special caution is now advised for high-risk patients, such as those with anatomical irregularities or undergoing CPR.

Recalled Products Include:

• Product Names and Product Codes:
  • Impella 5.0  Blood Pump, Product Number 005062
  • Impella CP  Blood Pump, Product Number 0048-0032
  • Impella 2.5 Blood Pump, Product Number 005042
  • Impella CP with SmartAssist Blood Pump, Product Numbers 0048-0024, 0048-0045, 1000080
  • Impella LD Blood Pump, Product Number 005082
  • Impella 5.5 with SmartAssist  Blood Pump, Product Numbers 0550-0008 And 1000100
• Distribution Dates: May 1, 2021 to present
• Devices Recalled in the U.S.: 7,895
• Date Initiated by Firm: June 14, 2023

While Abiomed maintains that the pumps remain on the market and available for clinical use, the sheer scale of the recall and the severity of the associated risks have raised eyebrows throughout the medical community.

An Abiomed spokesperson sought to reassure stakeholders, stating that the updated instructions provide “stronger technical guidance around implantation and repositioning, emphasizing specific cardiac and peripheral vascular anatomic considerations.”

However, this latest setback is merely the culmination of a troubling pattern that has emerged over the past 12 months.

Not the first Abiomed Recall.

In June 2023, Abiomed initiated a recall of select Impella RP Flex pumps due to an elevated risk of life-threatening blood clots. Just weeks later, the company warned of potentially fatal interactions between its heart pumps and transcatheter aortic valve replacement (TAVR) stents, with the FDA receiving four reports of related deaths.

April 2023 brought yet another recall, this time flagging an unacceptably high rate of purge fluid leaks in the Impella 5.5 pump with SmartAssist. This cascade of safety concerns prompted the FDA to issue a scathing warning letter in September, citing a litany of quality control and regulatory compliance failures.

Among the most damning findings, the agency revealed that Abiomed had knowingly delayed issuing the Impella 5.5 recall, despite being aware of the elevated leak rate well before the FDA’s inspection. Moreover, the company was found to have incorporated unauthorized software into its pumps, effectively circumventing the agency’s rigorous premarket approval process.

Regulatory Repercussions and Legal Fallout

In the wake of these revelations, Abiomed now faces intense scrutiny from both regulatory bodies and the legal community. The FDA’s warning letter represents a stern rebuke and a potential precursor to more severe enforcement actions, such as fines or product seizures.

Concurrently, a growing chorus of product liability lawsuits is taking shape, with plaintiffs alleging that Abiomed’s negligence and disregard for patient safety have resulted in catastrophic injuries and wrongful deaths. These cases could potentially expose the company to significant financial and reputational harm.

If you or someone you love has suffered any Abiomed Impella heart pump problems contact the Schmidt National Law Group today for a free case evaluation. Use the 100% Secure form on this page, or call us direct at 1-800-631-5656 to start the lawsuit claims process.

As the legal and regulatory battles unfold, one thing is clear: Abiomed’s once-sterling reputation as a pioneer in cardiovascular innovation has been tarnished. Restoring public trust and regaining regulatory compliance will be an uphill battle, requiring a comprehensive overhaul of the company’s quality control systems and a renewed commitment to transparency and patient safety.

Impella’s Checkered Past: A Retrospective

To fully grasp the gravity of Abiomed’s current predicament, it is instructive to examine the Impella line’s tumultuous history. Originally introduced in the late 1990s, these minimally invasive heart pumps were hailed as a revolutionary advancement in the treatment of acute heart failure and cardiogenic shock.

However, even in its early years, the Impella was no stranger to controversy. In 2005, the FDA issued a Class I recall for the Impella LD due to a software glitch that could potentially cause the pump to stop working mid-procedure. This was followed by a series of smaller recalls throughout the late 2000s and early 2010s, often related to manufacturing defects or labeling issues.

Despite these setbacks, Abiomed continued to aggressively market the Impella pumps, touting their purported superiority over more invasive ventricular assist devices (VADs) and intra-aortic balloon pumps (IABPs). This aggressive salesmanship, coupled with the allure of a minimally invasive alternative, fueled rapid adoption among interventional cardiologists and cardiac surgeons.

Scrutinizing the Clinical Evidence of the Impella device.

As the Impella’s popularity soared, so too did concerns over the paucity of robust clinical data supporting its widespread use. While Abiomed consistently cited a handful of small, industry-sponsored studies demonstrating favorable outcomes, independent researchers and clinicians remained skeptical.

In 2012, a landmark study published in the Journal of the American Medical Association (JAMA) delivered a scathing rebuke to Abiomed’s claims. The randomized controlled trial, which compared the Impella 2.5 to the more conventional IABP in patients undergoing high-risk percutaneous coronary intervention (PCI), found no significant difference in major adverse cardiac events or mortality between the two groups.

This seminal study was followed by a string of meta-analyses and observational studies that similarly failed to demonstrate a clear survival advantage for the Impella over its cheaper, less invasive counterparts. Critics argued that the device’s purported benefits did not justify its substantially higher cost and associated risks.

Abiomed’s Ethical Quandaries and Conflicts of Interest

As the clinical debate raged on, a parallel controversy emerged surrounding Abiomed’s marketing practices and alleged conflicts of interest. In 2015, the U.S. Department of Justice launched an investigation into whether the company had engaged in illegal kickback schemes by providing improper incentives to physicians who used the Impella pumps.

The probe ultimately resulted in a $3.1 million settlement, with Abiomed admitting no wrongdoing but agreeing to implement robust compliance measures. However, the damage to the company’s reputation was already done, with many in the medical community questioning the integrity of the clinical data and the potential for undue influence on prescribing patterns.

A Pivotal Moment for Abiomed and the Medical Device Industry

The challenges facing Abiomed are daunting, but the stakes could not be higher. As a pioneer in the field of minimally invasive cardiac support, the company’s actions will reverberate throughout the medical device industry, shaping perceptions of innovation, regulation, and patient safety for years to come.

Whether Abiomed emerges from this crucible as a reformed and trustworthy leader or succumbs to the weight of its missteps remains to be seen. One thing, however, is certain: the path forward will be arduous, requiring a steadfast commitment to transparency, accountability, and an unwavering dedication to the well-being of the patients it serves. The Schmidt National Law Group intends to hold Abiomed accoutable for the harm and suffering caused from the this faulty device.

Source:

https://www.fda.gov/medical-devices/medical-device-recalls/abiomed-recalls-all-impella-left-sided-blood-pumps-risk-motor-damage-after-contact-transcatheter

Page: Abiomed Heart Pump Recall Lawsuit Claims and Settlements Updated on July 12, 2024.